Edesa Biotech reports Q1 EPS (13c) vs. (33c) last year

"We are pleased to start off the year with three major pieces of good news," said Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech. "Overall, this was a strong quarter across our operations, and we look forward to building on this momentum, including making use of our expanded access under Fast Track and advancing our strategic discussions with potential commercialization and licensing partners. We see significant opportunities for our late-stage ARDS, ACD and vitiligo assets, and look forward to sharing our clinical and operational progress, including important upcoming regulatory milestones."